GSDMD and neoplasm: Metformin and Compound C, together with other GSDMD-targeted chemicals including Necrosulfonamide (NSA), disulfiram and Dimethylformamide (DMF) [14, 42, 43], may promote the development of pharmaceutical strategies to improve the outcomes of tumor and inflammatory diseases.